Entrada Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B.
Rule 10b5-1 Trading Arrangements
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 ornon-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2023, our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Action | Date | Type of Trading Arrangement | Nature of Trading Arrangement | Total Shares to be Sold | Expiration Date | |
| Natarajan Sethuraman (Chief Scientific Officer) | Adopt | 12/14/2023 | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Sale of the Company's common stock pursuant to the terms of the plan | 33,856 (1) | 4/13/2025 |
(1)Subject to increase based on any shares not sold under a previous 10b5-1 plan which will expire in April of 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.